CSCO vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 29, 2026

CSCO

54.2
AI Score
VS
CSCO Wins

MRNA

39.6
AI Score

Investment Advisor Scores

CSCO

54score
Recommendation
HOLD

MRNA

40score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CSCO MRNA Winner
Revenue 46.07B 534.00M CSCO
Net Income 9.41B -2.13B CSCO
Net Margin 20.4% -397.9% CSCO
Operating Income 11.10B -2.20B CSCO
ROE 19.3% -31.4% CSCO
ROA 7.5% -19.4% CSCO
Total Assets 125.55B 10.96B CSCO
Cash 7.08B 1.72B CSCO
Debt/Equity 0.47 0.09 MRNA
Current Ratio 0.92 2.29 MRNA
Free Cash Flow 7.77B -1.25B CSCO

Relative Price Performance (Last 90 Days)

CSCO 1M: +7.5% · 3M: -0.8% MRNA 1M: +40.0% · 3M: +156.6%

Current Technical Phase

CSCO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 66

RSI (14): 66.1 · Price: $117.39

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (49.6% over 20 days), RSI 64

RSI (14): 63.6 · Price: $196.48

Fundamentals Snapshot

Metric CSCO MRNA
Market Cap — —
Forward P/E 24.5 -41.0
Trailing P/E 33.9 —
Revenue (TTM) — —
Revenue Growth 0.2% 0.0%
Gross Margin 0.6% -0.7%
Operating Margin 0.3% -5.6%
EPS 3.48 -7.36
Dividend Yield 0.01% —

Frequently Asked Questions

Based on our detailed analysis, CSCO is currently the stronger investment candidate, winning 9 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.